Enterprise Value

242.9M

Cash

75.28M

Avg Qtr Burn

-3.119M

Short % of Float

0.25%

Insider Ownership

0.00%

Institutional Own.

19.76%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NBTXR3 +/- Cetuximab Details
Head and neck cancer, Cancer

Phase 3

Interim Update

RT + NBTXR3 + Chemotherapy Details
Cancer, Esophageal cancer

Phase 1/2

Data readout

RT + NBTXR3 Details
Cancer, Pancreatic cancer

Phase 1b

Data readout

NBTXR3 + Anti-PD-1 Details
Head and neck cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s

Phase 1

Data readout

RT + NBTXR3 Details
Cancer, Non-small cell lung carcinoma

Phase 1

Data readout